Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 – Medical Marijuana Program Connection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced successful completion of preclinical ADME and toxicology studies conforming to earlier positive results from PK animal studies and supportive of Enveric’s clinical design objectives for reduced overall side ef

Source link